Next-Generation Immunotherapies Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Regeneron, Boehringer Ingelheim, Sanofi, AstraZeneca, Roche, Merck, Incyte, GSK, Novartis

Next-generation immunotherapies market is expected to grow significantly during the forecast period (2023–2032) owing to the increasing number of cancer cases in the 7MM, accompanied by the introduction of novel and innovative therapies, overcoming the limitations of the current treatment regimen and leading to an increasing number of patients being treated by next-generation immunotherapies. 

LAS VEGAS, April 20, 2023 /PRNewswire/ -- DelveInsight's Next-Generation Immunotherapies Competitive Landscape report delivers an in-depth understanding of the next-generation immunotherapies and the next-generation immunotherapies market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Next-Generation Immunotherapies Market Report

• DelveInsight analysis shows that the next-generation immunotherapies market is expected to grow positively due to several underline factors during the study period (2019–2032).
• Leading next-generation immunotherapies companies such as Regeneron Pharmaceuticals, Boehringer Ingelheim, MacroGenics, MereoBiopharma, Hubao Biopharm, Shanghai Huaota Biopharmaceutical Co., Ltd., Kymab Limited, Sanofi, Alpine Immune Sciences, Inc., Xencor, Inc., Shanghai EpimAb Biotherapeutics Co., Ltd., GlaxoSmithKline, Novartis Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, AstraZeneca, Hoffmann-La Roche, Immunomic Therapeutics, Inc., Indaptus Therapeutics, Inc, Merck KGaA, Menarini Group, and others are developing novel next-generation immunotherapies that can be available in the next-generation immunotherapies market in the coming years.
• Some key next-generation immunotherapies include Fianlimab (REGN-3767), Tebotelimab (MGD013), Ezabenlimab (BI-754091), MGC 018, Etigilimab, INCAGN02385, HB-0036, HB0036, KY1044 and atezolizumab, AZD2936, ALPN-101, Tepotinib, XmAb22841, EMB-02, TSR-022, MBG453, BMS-986213, Pemigatinib, AZD7789, RO7247669, ITI-1001, Decoy20, Avelumab, MEN1611, and others.
• Several next-generation immunotherapies are awaiting approval, while some next-generation immunotherapies are in the advanced stages of development. 
• The emerging trend in next-generation immunotherapies with continuous headway movement along with new emerging technologies for developing targeted therapies lightens the hopes for better therapeutic alternatives.

Discover which next-generation immunotherapies are expected to grab the major next-generation immunotherapies market share @ Next-Generation Immunotherapies Market Report

Next-Generation Immunotherapies Overview

Cancer immunotherapy uses the patient's own immune system to combat cancer, as opposed to conventional cancer medicines, which directly target tumor cells. Immune checkpoints are pathways with inhibitory or stimulatory properties that help the immune response. The cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is an inhibitory checkpoint, as are the programmed cell death receptor-1 (PD-1) and programmed cell death ligand-1 (PD-L1).

The existing situation presents significant challenges for future advancement. One key problem is the scarcity of major biomarkers, resulting in the necessity for various clinical study designs for efficacy evaluation. New immune checkpoints with either stimulatory or inhibitory functions are emerging, with important roles in regulating T cell response but also affecting other innate immune response effectors (e.g., natural killer). TIGIT, ICOS, OX-40, LAG-3, TIM-3, B7-H3, and other targets are gaining interest as next-generation immunotherapies progress.

Learn more about next-generation immunotherapies for cancer therapy @ Next-Generation Immunotherapies 

Next-Generation Immunotherapies Market Insights

Cancer immunotherapy is fast advancing and is now regarded as the "fifth pillar" of cancer therapy, alongside surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The most popular cancer immunotherapy involves antibodies to inhibitory immune checkpoint molecules. The immune system is a network of cells, tissues, and organs that work together to protect the body from outside invaders such as bacteria or viruses. Lymphocytes are a type of white blood cell (WBC) that plays a critical role in bodily defense. Natural killer (NK) cells, B cells, and T cells are the three major kinds of lymphocytes.

The immune system is divided into two parts: the humoral (also known as antibody-mediated) immune response and the cell-mediated immunological response. These two sides collaborate to maintain the body free of infections. B-cells produce antibodies in the blood as part of the humoral immune response, which aids in the fight against infections in the lymph or blood and provides long-term immunity against subsequent infections. Immunotherapy is classified into several kinds, including checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccines, virus therapies, adoptive cell transfer and T-cell therapy, and targeted therapies. Immunotherapy has become a key focus of anticancer therapeutic regimens with good reason: when it succeeds, patients can have long-lasting antitumor immune responses that destroy primary tumors and metastasis lesions.

Next-generation immunotherapies are currently developing and target a wide spectrum of immunological targets. Of these immunotherapies under development, the most famous types are Lymphocyte Activation Gene 3 (LAG-3) inhibitors and T-Cell immunoglobulin and ITIM domain (TIGIT) inhibitors, which are closely followed by other potential types like TIM-3, B7 homolog 3 (B7-H3, also known as CD276), V-domain Ig suppressor of T cell activation (VISTA, also known as PD-1 Homolog), OX40 agonists, and Inducible co-stimulator (ICOS).

To know more about next-generation immunotherapies treatment, visit @ Next-Generation Immunotherapies Analysis

Key Next-Generation Immunotherapies Drugs and Companies

• Fianlimab (REGN-3767): Regeneron Pharmaceuticals
• Tebotelimab (MGD013): MacroGenics
• Ezabenlimab (BI-754091): Boehringer Ingelheim
• MGC 018: MacroGenics
• Etigilimab: MereoBiopharma
• INCAGN02385: Incyte Corporation
• HB-0036: Hubao Biopharm
• HB0036: Shanghai Huaota Biopharmaceutical Co., Ltd.
• KY1044 and atezolizumab: Kymab Limited/Sanofi
• AZD2936: AstraZeneca
• ALPN-101: Alpine Immune Sciences, Inc.
• Tepotinib: Merck KGaA
• XmAb22841: Xencor, Inc.
• EMB-02: Shanghai EpimAb Biotherapeutics Co., Ltd.
• TSR-022: GlaxoSmithKline
• MBG453: Novartis Pharmaceuticals
• BMS-986213: Bristol-Myers Squibb
• Pemigatinib: Incyte Corporation
• AZD7789: AstraZeneca
• RO7247669: Hoffmann-La Roche
• ITI-1001: Immunomic Therapeutics, Inc.
• Decoy20: Indaptus Therapeutics, Inc
• Avelumab: Merck KGaA
• MEN1611: Menarini Group

Learn more about the FDA-approved next-generation immunotherapies @ Approved Next-Generation Immunotherapies 

Next-Generation Immunotherapies Market Dynamics

The next-generation immunotherapies market dynamics are expected to change in the coming years. Several major next-generation immunotherapies market competitors, such as Regeneron, are working hard to create next-generation immunotherapies. In addition, strong national organizations and networks (ASCO, ASH, NCCN, etc.) are also working in the next-generation immunotherapies market.  Moreover, new techniques centered on inhibiting immunological checkpoint regulators with T-cell treatments have ushered in a new era of cancer immunotherapies. Companies are using new emerging technologies, such as mRNA technology, ImPACT, and ComPACT-based technology, to assist them in introducing viable medications.

Furthermore, the pipeline of next-generation immunotherapies is very robust; many potential therapies are being investigated for the treatment of Next Generation Immunotherapies, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period. The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate are likely to boost the growth of the next-generation immunotherapies market in the 7MM. 

However, several factors are impeding the growth of the next-generation immunotherapies market. Immunotherapy development is exceedingly expensive, occasionally impacting companies' R&D activities due to a lack of finance. Moreover, there are no good tools for calculating and reporting the tumor mutation burden (TMB). Furthermore, the lack of reimbursement policies for most cancer medicines is also a big threat to the cancer market. In addition, the exorbitant expense of medication therapy will put medical oncology therapies out of reach for many people. Moreover, the next-generation immunotherapies market growth may offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Scope of the Next-Generation Immunotherapies Market Report

• Therapeutic Assessment: Current Marketed and Emerging Next-Generation Immunotherapies 
• Next-Generation Immunotherapies Market Dynamics: Attribute Analysis of Emerging Next-Generation Immunotherapies 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Next-Generation Immunotherapies Market Access and Reimbursement

Discover more about next-generation immunotherapies in clinical development @ Next-Generation Immunotherapies in Clinical Trials

Table of Contents

Related Reports

LAG-3-Next Generation Immunotherapy Market

LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast – 2035 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key LAG-3-next-generation immunotherapy companies, including Bristol-Myers Squibb, Merck Sharp & Dohme Corp., MacroGenics, Immutep, Incyte Corporation, among others.

TIM-3-Next Generation Immunotherapy Market

TIM-3-Next Generation Immunotherapy Competitive Landscape, and Market Forecast – 2035 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key TIM-3 next-generation immunotherapy companies, including GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, among others.

ICOS-Next Generation Immunotherapy Market 

ICOS-Next Generation Immunotherapy Competitive Landscape, and Market Forecast – 2035 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ICOS-next-generation immunotherapy companies, including Jounce Therapeutics, GlaxoSmithKline, Kymab, among others.

Cancer Therapy Market

Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, among others.

Oncology Drugs Market

Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

LAG 3: A Promising Next Generation Cancer Immunotherapy

ENHERTU's Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg